

1 **A Phenome-Wide Association Study of genes associated with COVID-19 severity reveals** 2 **shared genetics with complex diseases in the Million Veteran Program**

3
4 Anurag Verma, PhD^{1,9¶}; Noah Tsao, BS^{1,11¶}; Lauren Thomann, MPH²; Yuk-Lam Ho⁷; Rotonya Carr,
5 MD^{1,10}; Dana Crawford, PhD^{19,22,23}; Jimmy T. Eford, PhD¹⁶; Jennifer Huffman, PhD²; Adriana Hung,
6 MD^{17,20}; Kerry Ivey, PhD^{9,21,22}; Sudha Iyengar, PhD^{4,22}; Michael Levin, MD¹⁰; Shiuh-Wen Luoh, MD,
7 PhD^{3,24}; Julie Lynch, PhD⁵; Pradeep Natarajan, MD, MMSc^{2,15,31,32}; Saiju Pyarajan, PhD^{2,12}; Alexander
8 Bick MD, PhD^{2,28}; Lauren Costa⁷; Giulio Genovese, PhD^{32,33,34}; Richard Hauger, MD³⁵; Ravi
9 Madduri^{36,37}; Gita Pathak PhD^{6,42}; Renato Polimanti PhD^{6,42}; Benjamin Voight, PhD^{1,9,26,27}; Marijana
10 Vujkovic, PhD^{1,10}; Maryam Zekavat, BSc^{2,38,39}; Hongyu Zhao, PhD^{6,39,40}; Marylyn D Ritchie, PhD³; VA
11 *Million Veteran Program COVID-19 Science Initiative*, Kyong-Mi Chang, MD^{1,10}; Kelly Cho, PhD⁷; Juan
12 P. Casas, MD, PhD^{7,13}; Philip S. Tsao, PhD^{8,41}; J. Michael Gaziano, MD, MPH^{7,13}; Christopher
13 O'Donnell, MD, MPH^{2,12,13}; Scott Damrauer, MD^{1,11*}; Katherine Liao, MD, MPH^{2,12,13*}

14
15 ¹ Corporal Michael Crescenz VA Medical Center, Philadelphia, Philadelphia, USA

16 ² VA Boston Healthcare System, Boston, Massachusetts, USA

17 ³ VA Portland Health Care System, Portland OR, USA

18 ⁴ Louis Stokes Cleveland VA Medical Center, Cleveland, OH, USA

19 ⁵ VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah, USA.

20 ⁶ VA Connecticut Healthcare System, West Haven, CT, USA

21 ⁷ Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare
22 System, Boston, Massachusetts, USA

23 ⁸ VA Palo Alto Health Care System, Palo Alto, California, USA

24 ⁹ Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania,
25 USA.

26 ¹⁰ Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania,
27 USA

28 ¹¹ Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania,
29 USA

30 ¹² Harvard Medical School, Boston, Massachusetts, USA.

31 ¹³ Brigham and Women's Hospital, Boston, Massachusetts, USA.

32 ¹⁴ Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA.

33 ¹⁵ Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

34 ¹⁶ Cardiovascular Medicine Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical
35 School, Boston, Massachusetts, USA

36 ¹⁷ Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University,
37 Portland, Oregon, USA

38 ¹⁸ College of Nursing and Health Sciences, University of Massachusetts, Lowell, Massachusetts, USA.

39 ¹⁹ Cleveland Institute for Computational Biology, Department of Population and Quantitative Health Sciences, Case
40 Western Reserve University, Cleveland, Ohio, USA.

41 ²⁰ Cooperative Studies Program Epidemiology Center, Health Services Research and Development, DVAHCS
42 (Duke University Affiliate), Durham, North Carolina, USA.

43 ²¹ Tennessee Valley Healthcare System (Nashville VA) & Vanderbilt University, Nashville, Tennessee, USA.

44 ²² Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio,
45 USA.

46 ²³ Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio, USA

47 ²⁴ Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University,
48 Portland, Oregon, USA

49 ²⁵ Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA.

50 ²⁶ Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University
51 of Pennsylvania, Philadelphia, Pennsylvania, USA

52 ²⁷ Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania,
53 Philadelphia, Pennsylvania, USA

54 ²⁸ Vanderbilt University, Nashville, Tennessee, USA

55 ²⁹ South Australian Health and Medical Research Institute, Infection and Immunity Theme, South Australia,
56 Australia
57 ³⁰ Harvard T.H. Chan School of Public Health, Department of Nutrition, Massachusetts, USA
58 ³¹ Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
59 ³² Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard
60 & MIT, Cambridge, Massachusetts, USA
61 ³³ Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA
62 ³⁴ Department of Genetics, Harvard Medical School, Boston, MA, USA
63 ³⁵ Department of Psychiatry, University of California, San Diego, La Jolla, CA; Center of Excellence for Stress and
64 Mental Health, VA San Diego Healthcare System, San Diego, CA, USA
65 ³⁶ University of Chicago Consortium for Advanced Science and Engineering, The University of Chicago, Chicago,
66 Illinois, USA
67 ³⁷ Data Science and Learning Division, Argonne National Laboratory, Lemont, Illinois.
68 ³⁸ Broad Institute of MIT & Harvard, Cambridge, MA, USA
69 ³⁹ Yale School of Medicine New Haven, CT, USA
70 ⁴⁰ Computational Biology and Bioinformatics Program, Yale University, New Haven, CT, USA
71 ⁴¹ Department of Medicine (Cardiovascular Medicine), Stanford University School of Medicine, Stanford, CA, USA
72 ⁴² Department of Psychiatry, Yale School of Medicine, Connecticut, USA

73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98

99 Joint Authorship

100 [¶]These authors contributed equally to this work

101 *These authors jointly supervised this work

102 Correspondence

103 Anurag Verma: anurag.verma@pennmedicine.upenn.edu, Katherine Liao: kliao@bwh.harvard.edu

104
105

106

107 **Abstract**

108 **Background** There are certain pre-existing conditions which leads in increased risk of
109 coronavirus disease 2019 (COVID-19) severity and mortality. The objective of this study is to
110 determine shared genetic architecture between COVID-19 severity and other medical conditions
111 using electronic health record (EHR) data from diverse patient populations.

112 **Methods and Findings:** We conducted Phenome-wide association study (PheWAS) of genetic
113 variants associated with severe COVID-19 in two biobanks with EHR and genomic data: 1)
114 Veteran Affairs (VA) Million Veteran Program (MVP), 2) United Kingdom Biobank (UKBB).
115 Genetic variants associated with critical illness (n=48) or hospitalization (n=39) due to COVID-
116 19 from COVID-19 Host Genetics Initiative genome-wide association studies. Phenotypes
117 defined by International Classification of Diseases (ICD) codes mapped to clinically relevant
118 groups using published PheWAS methods; pre-COVID-19 data used to avoid potential
119 confounding. Among 455,683 US Veterans from MVP, variants associated with severe COVID-
120 19 tested for association across 1,559 phenotypes; 353,365 UK Biobank participants, and 1,064
121 phenotypes tested. Genetic variants at *ABO* locus (rs550057, rs505922) associated with the
122 largest number of phenotypes ($n_{rs550057}=53$ and $n_{rs505922}=61$); strongest association with venous
123 embolism, odds ratio (OR)_{rs550057} 1.27 ($p=5.28 \times 10^{-116}$), and thrombosis OR_{rs505922} 1.31, $p=3.5$
124 $\times 10^{-183}$. Among 67 respiratory conditions tested, only idiopathic pulmonary fibrosis, OR_{rs2277732}
125 1.17, $p=1.3410^{-05}$, and asthma OR_{rs143334143} 0.94, $p=2.31 \times 10^{-04}$, shared variants with severe
126 COVID-19. The *RAVER1* locus (rs74956615) associated with reduced risk for autoimmune
127 conditions, e.g. psoriasis OR 0.71, $p=1.53 \times 10^{-22}$, rheumatoid arthritis, OR 0.78, $p=1.04 \times 10^{-09}$;
128 findings replicated in UKBB. A known functional missense variant (rs34536443, *TYK2*) in the
129 region had the highest linkage disequilibrium with rs74956615, suggesting signal was likely

130 from *TYK2*. In MVP, PheWAS results stratified by genetic ancestry did not demonstrate
131 significant difference in associations across ancestry.

132 **Conclusions** Shared genetic architecture between COVID-19 severity and conditions related to
133 underlying risk factors for severe and poor COVID-19 outcomes; associations similar across
134 genetic ancestries. Divergent association between inflammatory conditions and severe COVID
135 may be explained by known pathway impairing signaling of inflammatory cytokines, reducing
136 risk for autoimmunity; same pathway reduces type 1 interferon signaling, critical for viral host
137 defense. Caution needed when targeting pathways that may balance immune tolerance and
138 immunodeficiency to treat COVID-19.

139

140 **Introduction**

141 A respiratory disease coronavirus disease-2019 (COVID-19) caused by a novel coronavirus was
142 identified in December 2019,¹ now known as severe acute respiratory syndrome coronavirus 2
143 (SARS-CoV-2). As of March 2021, the COVID-19 pandemic has resulted in the loss of over 2.6
144 million lives worldwide.² Identifying host genetic variants associated with severe disease from
145 COVID-19 can identify key pathways important in the pathogenesis of SARS-CoV2.
146 International efforts such as the COVID-19 Host Genetics Initiative (HGI)³ have meta-analyzed
147 genome-wide association study (GWAS) summary statistics at regular intervals to identify novel
148 genetic associations with COVID-19 severity. Thus far, ten independent variants associated with
149 COVID-19 severity at genome-wide significance have been identified, most notably at the *ABO*
150 locus.⁴ These GWASs have also identified variations in genes involving inflammatory cytokines
151 and interferon signaling pathways such as *IFNAR2*, *TYK2*, and *DPP9*.⁴

152 The unprecedented availability of genome-wide data for COVID-19 provides an
153 opportunity to study clinical conditions that share genetic risk factors for COVID-19 severity.
154 Examining known conditions, each with a body of knowledge regarding important pathways and
155 targets, may in turn improve our understanding of pathways relevant for COVID-19 severity and
156 inform the development of novel treatments against this pathogen. The Phenome-Wide
157 Association Study (PheWAS) is an approach for simultaneously testing genetic variants'
158 association with a wide spectrum of conditions and phenotypes.⁵ Mega-biobanks such as the
159 Veteran's Affairs (VA) Million Veterans Program (MVP) and the UK Biobank (UKBB), both
160 with genotypic data on over 500,000 participants linked with Electronic Health Record (EHR)
161 data containing rich phenotypic data, enables large-scale PheWAS. Moreover, MVP has the

162 highest racial and ethnic diversity of the major biobanks affording an opportunity to compare
163 whether associations are similar across genetic ancestries.⁶

164 The objective of this study was to use existing clinical EHR data to identify conditions
165 that share genetic variants with COVID-19 severity using the disease-agnostic PheWAS
166 approach. Since COVID-19 is a new condition, identifying existing conditions which share
167 genetic susceptibility may allow us to leverage existing knowledge from these known conditions
168 to provide context regarding important pathways for COVID-19 severity.

169 **Methods**

170 **Data sources**

171 The VA MVP is a national cohort launched in 2011 designed to study the contributions of
172 genetics, lifestyle, and military exposures to health and disease among US Veterans.⁶ Blood
173 biospecimens were collected for DNA isolation and genotyping, and the biorepository was
174 linked with the VA EHR, which includes diagnosis codes (International Classification of
175 Diseases ninth revision [ICD-9] and tenth revision [ICD-10]) for all Veterans followed in the
176 healthcare system up to September 2019. The single nucleotide polymorphism (SNP) data in the
177 MVP cohort was generated using a custom Thermo Fisher Axiom genotyping platform called
178 MVP 1.0. The quality control steps and genotyping imputation using 1000 Genomes
179 cosmopolitan reference panel on the MVP cohort has been described previously.⁷

180 UKBB is a population-based cohort of approximately 500,000 subjects from the UK between 49
181 and 69 years of age and served as the replication cohort. Participants were enrolled between
182 2006 and 2010 and consented for the prospective collection of health records and lifestyle,

183 imaging, and genetic data. The phenotype data included ICD-10 diagnosis codes up to March
184 2019.

185 Genetic variant selection

186 An overview of the analytic workflow is outlined in Fig 1. Variants were derived from the
187 COVID-19 HGI GWAS meta-analysis release v4³. In this study, we analyzed the following HGI
188 GWAS summary statistics: 1) hospitalized and critically ill COVID-19 vs. population controls
189 denoted as “A2” in HGI, and referred to as “critical COVID” in this study, and 2) hospitalized
190 because of COVID-19 vs. population controls, denoted as “B2” in HGI, referred to as
191 “hospitalized COVID” in this study³. For each GWAS, variants with a Benjamini-Hochberg false
192 discover rate (FDR) corrected p-value < 0.1 were selected as candidate lead SNPs (853
193 associated with critical COVID, and 902 associated with hospitalized COVID). Variants with r^2
194 < 0.1 were clustered within a 250 kb region according to 1000 Genomes phase 3 transethnic
195 reference panel⁸, resulting in 48 independent variants associated with critical COVID and 39
196 variants associated with hospitalized COVID summary statistics. The lead variants from each set
197 of GWAS summary statistics are available in eTable 1.

198 Outcomes

199 For both MVP and UKBB, clinical data prior to the onset of the COVID-19 pandemic were used
200 to reduce potential confounding bias from SARS-CoV-2 infection on existing conditions.
201 Briefly, phenotypes were defined by phecodes, used in prior PheWAS studies^{5,9}. Each phecode
202 represents ICD codes grouped into clinically relevant phenotypes for clinical studies. For
203 example, the phecode “deep venous thrombosis” includes “venous embolism of deep vessels of
204 the distal lower extremities,” and “deep venous thrombosis of the proximal lower extremity,”

205 both of which have distinct ICD codes. Using this approach, all ICD codes for all Veterans in
206 MVP were extracted and each assigned a phenotype defined by a phecode. ICD-9 and ICD-10
207 codes were mapped to 1876 phecodes, as previously described.^{5,9}

208 For each phecode, participants with ≥ 2 phecode-mapped ICD-9 or ICD-10 codes were defined as
209 cases, whereas those with no instance of a phecode-mapped ICD-9 or ICD-10 code were defined
210 as controls. Based on our previous simulation studies of ICD codes from EHRs, we excluded
211 phecodes with < 200 cases from the analysis¹⁰ and we applied this threshold in each ancestry
212 group. Thus, 1,520 (EUR), 1206 (AFR), 858 (HIS), 176 (ASN) phecodes in the MVP cohort
213 were analyzed. The same process was applied to UKBB, resulting in 1,064 phecodes from 1,615
214 phecodes.

215 Phenome-wide association studies

216 The primary PheWAS analysis used SNPs identified from the HGI GWAS of critical and
217 hospitalized COVID, and tested association of these SNPs with phenotypes extracted from the
218 EHR data prior to the COVID-19 pandemic. Logistic regression using PLINK2 to examine
219 SNPs' association with phecodes and firth regression was applied when logistic regression model
220 failed to converge. Regression models were adjusted for sex, age (at enrollment), age squared,
221 and the first 20 principal components. Genetic ancestry was determined using the HARE method
222 for four major groups: African (AFR), Asian (ASN), Hispanic (HIS), and European (EUR)
223 ancestry¹¹. Ancestry-specific PheWAS was first performed in these four groups, and then
224 summary data were meta-analyzed using an inverse-variance weighted fixed-effects model
225 implemented in the PheWAS R package⁹. We assessed heterogeneity using I^2 and excluded any
226 results with excess heterogeneity ($I^2 > 40\%$).

227 To address multiple testing, FDR $p < 0.1$ was considered significant. In the PheWAS analysis, p
228 $< 2.44 \times 10^{-4}$ (critical COVID lead variants) and $p < 3.18 \times 10^{-4}$ (hospitalized COVID lead
229 variants) were considered significant. In the main manuscript we highlight PheWAS significant
230 associations using FDR < 0.1 and an effect size associated with increased or reduced risk for a
231 condition by 10%, with complete PheWAS results in eTable 2 and eTable 3. Replication of
232 MVP PheWAS results were performed in UKBB among individuals of European descent due to
233 small sample size of other ancestries in UKBB.

234 **Results**

235 We studied 453,699 MVP participants, with mean age 68 years (SD), 89% male, with 32%
236 participants from non-European ancestry (Table 1). The PheWAS was performed on 48 genetic
237 variants associated with critical COVID-19, and 39 genetic variants associated with hospitalized
238 COVID, across 1,559 phenotypes.

239 From the trans-ethnic meta-analysis, we identified 109 phenotypes significantly associated with
240 critical COVID GWAS-identified variants, and 118 associations with hospitalized COVID
241 GWAS-identified lead variants (FDR, $p < 0.1$). Five variants were common to both severe and
242 hospitalized COVID and had significant PheWAS associations, namely, variations nearest to the
243 genes *ABO* (rs550057 and rs505922), *DPP9* (rs2277732), *HLA-DPBI* (rs143334143), and
244 *CCHCR1* (rs9501257) (eTable 2 and eTable 3).

245 Association of ABO loci with known risk factors and outcomes related to COVID-19 severity

246 In the transeethnic meta-analysis, the phenotypes with the strongest association with variants near
247 *ABO* locus (rs550057 and rs505922) was “venous embolism and thrombosis” ($OR_{\text{critical_PheWAS}} =$

248 1.27 [1.24 - 1.29], $P_{\text{critical_PheWAS}} = 5.28 \times 10^{-116}$; $OR_{\text{hospitalized_PheWAS}} = 1.31$ [1.29 - 1.34],
249 $P_{\text{hospitalized_PheWAS}} = 3.53 \times 10^{-183}$, Fig 2). The ABO loci had the largest number of significant
250 PheWAS association findings, accounting for 48% (53/109) of significant phenotype
251 associations in the critical COVID PheWAS, and 51% (61/118) in the hospitalized COVID
252 PheWAS. As expected, conditions associated with the ABO locus, such as venous embolism and
253 thrombosis, hypercoagulable state, type 2 diabetes, coronary atherosclerosis, have been reported
254 as risk factors for or are complications associated with COVID-19 severity and mortality (Fig 2,
255 eTable 2 and eTable 3).

256 Associations between variants associated with COVID-19 severity and respiratory conditions
257 and infections

258 Among respiratory conditions, only two diseases had significant associations (FDR < 0.1) shared
259 with genetic variants associated with severe COVID-19. The most significant association was
260 observed between rs2277732 (*DPP9*) and idiopathic fibrosing alveolitis (OR = 1.17 [1.08 –
261 1.26]; $P = 5.34 \times 10^{-5}$), also known as idiopathic pulmonary fibrosis (IPF). The association
262 between *DPP9* variants and IPF has been reported in previous studies.¹² However, the
263 association of genetic variants with other respiratory conditions may represent novel findings:
264 the association of intronic variant rs143334143 in *CCHCR1* with asthma (OR = 0.94 [0.92 -
265 0.97], $P = 2.31 \times 10^{-4}$). We did not detect associations between any of the variants and either
266 other respiratory conditions or infectious diseases. (eTable 3).

267 Associations between variants associated with COVID-19 severity and reduced risk for certain
268 phenotypes

269 A subset of variants associated with severe COVID were also associated with a reduced risk for
270 certain conditions, many of which were autoimmune conditions (Table 2). The rs74956615-A
271 allele of *RAVER1*, a lead variant from the hospitalized COVID GWAS was associated with a
272 reduced risk for psoriasis (OR = 0.71 [0.66- 0.76], $P = 1.5 \times 10^{-22}$), rheumatoid arthritis (RA)
273 (OR = 0.78 [0.72 - 0.84], $P = 4.6 \times 10^{-09}$), and psoriatic arthropathy (OR = 0.60 [0.50 - 0.71], $P =$
274 3.4×10^{-09}). Similarly, rs11085727-T at the *TYK2* locus identified as a lead variant in the HGI
275 critical COVID GWAS was associated with a reduced risk of psoriasis (OR = 0.88 [0.85 - 0.90],
276 $P = 1.35 \times 10^{-17}$) and psoriatic arthropathy (OR = 0.81 [0.75 -0.86], $P = 9.54 \times 10^{-10}$).

277 The association of the *RAVER1* variant with psoriasis and RA replicated in UKBB. Among the
278 353,365 EUR UKBB participants, the *RAVER1* variant was associated with a decreased risk for
279 psoriasis and RA (OR_{psoriasis} = 0.69, $P = 2.88 \times 10^{-05}$; OR_{RA} = 0.67, $P = 9.15 \times 10^{-07}$). *RAVER1*
280 was mentioned in prior RA GWAS' with the signal attributed to *TYK2*.¹³ The *TYK2* signal has
281 been mapped to a protein-coding variant (rs34536443) with predicted partial loss of function
282 (LOF) leading to a reduced risk of psoriasis, psoriatic arthropathy, and RA as well as other
283 autoimmune inflammatory conditions^{14,15}. The *RAVER1* variant (rs74956615) in this study is in
284 high linkage disequilibrium (LD) ($r^2 = 0.7$) with this *TYK2* protein-coding variant (S1 Fig), with
285 the same associations of reduced risk of psoriasis, psoriatic arthropathy, and RA. This suggests
286 that the *RAVER1* signal from our analysis is coupled with the protein-coding variant in *TYK2*
287 (rs34536443). The *TYK2* variant (rs11085727) associated with critical COVID was not in LD (r^2
288 =0.07) with the previously identified protein-coding variant in *TYK2* (rs34536443). To further
289 support these findings, we conducted PheWAS of rs34536443 in MVP and observed similar
290 association of reduced risk with aforementioned autoimmune inflammatory conditions (S2 Fig).

291 The PheWAS analyses performed across genetic ancestries observed similar findings as the
292 overall meta-analysis with fewer associations within each ancestry group due to smaller
293 population sizes (S3 Fig). Of note, SNP rs1396186 associated with hospitalized COVID didn't
294 had associations with obesity in meta-analysis ($P=0.06$; $I^2 = 84\%$). However, among Veterans of
295 African ancestry, this association was significant (OR = 1.13 [1.07 – 1.19]; $P = 8.79 \times 10^{-06}$) but
296 was not observed in the larger population of European descent (S3 Fig, panel B, S3 Table).
297 Another SNP, that passed rs1754680 was significantly associated with obesity among EUR
298 ancestry participants but not in other ancestry populations (S3 Table).

299 **Discussion**

300 In this large-scale PheWAS, we identified shared genetic architecture between variants
301 associated with severe COVID-19 and other complex conditions using data from MVP, one of
302 the largest and most diverse biobanks in the world, with replication in UKBB. Broadly, these risk
303 alleles identified conditions associated with risk factors for severe COVID-19 manifestations
304 such as T2D, ischemic heart disease across all ancestries, with a potentially stronger association
305 with obesity among Veterans of African ancestry. Phenotypes associated with poor outcomes
306 related to COVID-19 infection, including deep venous thrombosis and other thrombotic
307 complications, also shared variants associated with severe COVID-19. In contrast, among
308 respiratory conditions, only idiopathic pulmonary fibrosis and asthma shared genetic risk factors,
309 with the notable absence of an association with COPD and other respiratory infections. Finally,
310 we observed that variants associated with severe COVID-19 were associated with a reduced risk
311 of autoimmune inflammatory conditions, such as psoriasis, psoriatic arthritis, and RA.

312 A classic GWAS tests the association between millions of genetic variants with the presence or
313 absence of one phenotype, e.g., GWAS of deep venous thrombosis. In the COVID-19 HGI
314 GWAS, the “phenotype” was patients hospitalized for or critically ill from COVID-19.
315 Clinically, this population includes a mixture of patients with a complex list of medical
316 conditions at high risk for severe COVID complications and those who had actual complications
317 from COVID-19. Thus, we would anticipate that many of the significant phenotypes would be
318 associated with risk factors such as obesity and deep venous thrombosis. Notably, the clinical
319 data used in this study pre-dates the emergence of COVID-19 to reduce potential confounding
320 bias that can occur in a population infected with SARS-CoV-2, e.g. interaction between COVID-
321 19 and type 2 diabetes. Additionally, our findings suggest that the PheWAS approach can be a
322 useful tool to identify clinical factors related to emerging infectious diseases regarding severity
323 or complications when genomic data are available.

324
325 The PheWAS results of SNPs in the *ABO* locus served as a positive control for this study.
326 Genetic variations in *ABO* are an established risk factor for COVID-19 severity. Patients with
327 blood group A have a higher risk of requiring mechanical ventilation and extended ICU stay
328 compared with patients with blood group O.¹⁶ These same variations at *ABO* had known
329 associations with a spectrum of blood coagulation disorders identified in studies pre-dating
330 COVID-19.¹⁷⁻¹⁹ The PheWAS of *ABO* variants identified associations with increased risk of
331 deep vein thrombosis, pulmonary embolism, and other circulatory disorders, in line with prior
332 studies, and recent studies among patients hospitalized with COVID-19.²⁰⁻²⁴

333
334 Autoimmune conditions shared genetic variants with severe COVID-19, the direction of effect
335 was for a reduced odd of these conditions. Based on existing data, we believe known protein-

336 coding variants in *TYK2* (rs34536443, 1140A) drove the majority of the signal from *RAVER1*
337 with reduced risk of psoriasis, psoriatic arthritis, and RA; this signal is consistent with prior
338 reported associations of a protective effect of *TYK2* with these same conditions.^{13,14,15} Moreover,
339 recent studies exploring potentially important pathways for COVID-19 progression have
340 highlighted *TYK2* and its downstream signaling pathway through type 1 interferons as a
341 potential target for treatment.²⁵

342
343 The existing literature can help explain the dual association between reduced risk of autoimmune
344 conditions such as psoriasis and RA and increased risk of severe COVID via *TYK2*. *TYK2*, a
345 member of the Janus Kinase (JAK) family of genes, plays a key role in cytokine signal
346 transduction and the inflammatory response, particularly via IL-12, IL-23, and is also important
347 for IL-6 and IL-10 signaling (Fig 3).²⁶ Importantly, *TYK2* has a central role in type 1 interferon
348 signaling, part of the innate immune response blocking the spread of a virus from infected to
349 uninfected cells. Of interest is the *TYK2* variant represented by the SNP rs34536443 (P1104A)
350 resulting in partial LOF and reduced risk for several autoimmune disorders such as RA, type 1
351 diabetes, psoriasis, and psoriatic arthritis without evidence of significant immunodeficiency.^{14,27-}
352 ³⁰ However, humans with complete *TYK2* LOF have clinically significant immunodeficiency
353 with increased susceptibility to mycobacterial and viral infections.^{26,31}

354
355 The balance between immune tolerance and ability to mount a robust early inflammatory
356 response, and viral host defense may in part explain the mixed results of clinical trials using
357 immunosuppressive therapy in COVID-19 to date²⁵. Corticosteroid therapy may be beneficial in
358 later stages of COVID-19 infection but detrimental if used early in the disease presumably when
359 an early host defense response is important.³² Blocking the IL-6 pathway with tocilizumab did

360 not reduce mortality among hospitalized COVID-19 patients, but may be beneficial among later-
361 stage pulmonary damage^{33,34}. The evidence to date suggests that the ability to mount an early
362 inflammatory response is an important aspect in the control of COVID-19 infection and that
363 dampening inflammation early in the disease course may be detrimental.

364

365 **Limitations**

366 We note several limitations. First, the PheWAS was designed as a broad screen to test for
367 potentially clinically relevant associations between genes and phenotypes, with limited power to
368 detect associations among uncommon conditions, and when further stratified by genetic ancestry.
369 MVP is not a general US population-based cohort; however, results were replicated in UKBB, an
370 independent general population cohort. Findings from this study suggest that variants associated
371 with severe COVID-19 are also associated with reduced risk of having an autoimmune
372 inflammatory condition. However, the results cannot provide information on the impact of
373 actual SARS-CoV-2 infection in these individuals after diagnosis of an autoimmune disease.
374 Finally, the data strongly suggest but cannot confirm that the signal observed from *RAVER1*
375 arises from the previously identified and studied *TYK2* variant.

376

377 **Conclusions**

378 This PheWAS of genetic variants reported to associate with severe COVID-19 demonstrated
379 shared genetic architecture between COVID-19 severity and known underlying risk factors for
380 both severe COVID-19 and poor COVID-19 outcomes, rather than susceptibility to other viral
381 infections. Overall, the associations observed were generally consistent across genetic ancestries,
382 with a potential stronger association with obesity among Veterans of African ancestry compared
383 to European ancestry. The divergent association between severe COVID-19 and autoimmune

384 inflammatory conditions sheds light on the concept of a balance between immune tolerance and
385 immunodeficiency. This balance will be important when considering therapeutic targets for
386 COVID-19 therapies where pathways may control both inflammation and the viral host response.

387

388 **Funding**

389 This research is based on data from the Million Veteran Program, Office of Research and
390 Development, Veterans Health Administration, and was supported by award MVP035. This
391 publication does not represent the views of the Department of Veteran Affairs or the United
392 States Government. R.M.C. is supported by NIH grants R01 AA026302 and P30 DK0503060.
393 K.P.L. is supported by NIH P30 AR072577, and the Harold and Duval Bowen Fund.

394

395 **Conflict of Interest**

396 RMC has received research support from Intercept Pharmaceuticals, Inc and Merck & Co. MDR
397 is on the scientific advisory board for Goldfinch Bio and CIPHEROME. CJO is an employee of
398 Novartis Institute for Biomedical Research. PN reports grant support from Amgen, Apple,
399 AstraZeneca, Boston Scientific, and Novartis, personal fees from Apple, AstraZeneca,
400 Blackstone Life Sciences, Genentech, and Novartis, and spousal employment at Vertex, all
401 unrelated to the present work.

402

403

404

405 **Acknowledgements**

406 We are grateful to our Veterans for their contributions to MVP. Full acknowledgements for the
407 VA Million Veteran Program COVID-19 Science Initiative can be found in the supplementary
408 methods. We would like to thank the Host Genetic Initiative for making their data publicly
409 available (<https://www.covid19hg.org/acknowledgements/>). We would also like to acknowledge
410 Dr. Madhuvika Murgan for her insightful suggestion on the Fig 3. We used genotype and
411 phenotype data from the UK Biobank under project 32133.

412

413

414

415

416

417

418

419

420

421

422 References

- 423 1. CDC. About COVID-19 - CDC. : [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/cdcresponse/about-COVID-19.html)
424 [ncov/cdcresponse/about-COVID-19.html](https://www.cdc.gov/coronavirus/2019-ncov/cdcresponse/about-COVID-19.html)
- 425 2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real
426 time. *Lancet Infect Dis*. 2020;20(5):533-534. doi:10.1016/S1473-3099(20)30120-1
- 427 3. The COVID-19 Host Genetics Initiative, ganna andrea. *Mapping the Human Genetic*
428 *Architecture of COVID-19 by Worldwide Meta-Analysis*. Genetic and Genomic Medicine;
429 2021. doi:10.1101/2021.03.10.21252820
- 430 4. The GenOMICC Investigators, The ISARIC4C Investigators, The COVID-19 Human
431 Genetics Initiative, et al. Genetic mechanisms of critical illness in COVID-19. *Nature*.
432 2021;591(7848):92-98. doi:10.1038/s41586-020-03065-y
- 433 5. Denny JC, Ritchie MD, Basford MA, et al. PheWAS: demonstrating the feasibility of a
434 phenome-wide scan to discover gene-disease associations. *Bioinformatics*.
435 2010;26(9):1205-1210. doi:10.1093/bioinformatics/btq126
- 436 6. Gaziano JM, Concato J, Brophy M, et al. Million Veteran Program: A mega-biobank to
437 study genetic influences on health and disease. *J Clin Epidemiol*. 2016;70:214-223.
438 doi:10.1016/j.jclinepi.2015.09.016
- 439 7. Hunter-Zinck H, Shi Y, Li M, et al. Genotyping Array Design and Data Quality Control in
440 the Million Veteran Program. *Am J Hum Genet*. 2020;106(4):535-548.
441 doi:10.1016/j.ajhg.2020.03.004
- 442 8. 1000 Genomes Project Consortium, Auton A, Brooks LD, et al. A global reference for
443 human genetic variation. *Nature*. 2015;526(7571):68-74. doi:10.1038/nature15393
- 444 9. Carroll RJ, Bastarache L, Denny JC. R PheWAS: data analysis and plotting tools for
445 phenome-wide association studies in the R environment. *Bioinformatics*. 2014;30(16):2375-
446 2376. doi:10.1093/bioinformatics/btu197
- 447 10. Verma A, Bradford Y, Dudek S, et al. A simulation study investigating power estimates in
448 phenome-wide association studies. *BMC Bioinformatics*. 2018;19(1):120.
449 doi:10.1186/s12859-018-2135-0
- 450 11. Fang H, Hui Q, Lynch J, et al. Harmonizing Genetic Ancestry and Self-identified
451 Race/Ethnicity in Genome-wide Association Studies. *Am J Hum Genet*. 2019;105(4):763-
452 772. doi:10.1016/j.ajhg.2019.08.012
- 453 12. Allen RJ, Guillen-Guio B, Oldham JM, et al. Genome-Wide Association Study of
454 Susceptibility to Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med*.
455 2020;201(5):564-574. doi:10.1164/rccm.201905-1017OC

- 456 13. Eyre S, Bowes J, Diogo D, et al. High-density genetic mapping identifies new susceptibility
457 loci for rheumatoid arthritis. *Nat Genet.* 2012;44(12):1336-1340. doi:10.1038/ng.2462
- 458 14. Diogo D, Bastarache L, Liao KP, et al. TYK2 Protein-Coding Variants Protect against
459 Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on
460 Non-Autoimmune Complex Traits. Chiorini JA, ed. *PLOS ONE.* 2015;10(4):e0122271.
461 doi:10.1371/journal.pone.0122271
- 462 15. Dendrou CA, Cortes A, Shipman L, et al. Resolving TYK2 locus genotype-to-phenotype
463 differences in autoimmunity. *Sci Transl Med.* 2016;8(363):363ra149-363ra149.
464 doi:10.1126/scitranslmed.aag1974
- 465 16. Hoiland RL, Fergusson NA, Mitra AR, et al. The association of ABO blood group with
466 indices of disease severity and multiorgan dysfunction in COVID-19. *Blood Adv.*
467 2020;4(20):4981-4989. doi:10.1182/bloodadvances.2020002623
- 468 17. Zietz M, Zucker J, Tatonetti NP. Associations between blood type and COVID-19
469 infection, intubation, and death. *Nat Commun.* 2020;11(1):5761. doi:10.1038/s41467-020-
470 19623-x
- 471 18. Paranjpe I, Fuster V, Lala A, et al. Association of Treatment Dose Anticoagulation With In-
472 Hospital Survival Among Hospitalized Patients With COVID-19. *J Am Coll Cardiol.*
473 2020;76(1):122-124. doi:10.1016/j.jacc.2020.05.001
- 474 19. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
475 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From
476 the Chinese Center for Disease Control and Prevention. *JAMA.* Published online February
477 24, 2020. doi:10.1001/jama.2020.2648
- 478 20. Matsunaga H, Ito K, Akiyama M, et al. Transethnic Meta-Analysis of Genome-Wide
479 Association Studies Identifies Three New Loci and Characterizes Population-Specific
480 Differences for Coronary Artery Disease. *Circ Genomic Precis Med.* 2020;13(3):e002670.
481 doi:10.1161/CIRCGEN.119.002670
- 482 21. Plagnol V, Howson JMM, Smyth DJ, et al. Genome-wide association analysis of
483 autoantibody positivity in type 1 diabetes cases. *PLoS Genet.* 2011;7(8):e1002216.
484 doi:10.1371/journal.pgen.1002216
- 485 22. Reilly MP, Li M, He J, et al. Identification of ADAMTS7 as a novel locus for coronary
486 atherosclerosis and association of ABO with myocardial infarction in the presence of
487 coronary atherosclerosis: two genome-wide association studies. *Lancet Lond Engl.*
488 2011;377(9763):383-392. doi:10.1016/S0140-6736(10)61996-4
- 489 23. Trégouët D-A, Heath S, Saut N, et al. Common susceptibility alleles are unlikely to
490 contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS
491 approach. *Blood.* 2009;113(21):5298-5303. doi:10.1182/blood-2008-11-190389

- 492 24. Larson NB, Bell EJ, Decker PA, et al. ABO blood group associations with markers of
493 endothelial dysfunction in the Multi-Ethnic Study of Atherosclerosis. *Atherosclerosis*.
494 2016;251:422-429. doi:10.1016/j.atherosclerosis.2016.05.049
- 495 25. Gaziano L, Giambartolomei C, Pereira AC, et al. *Actionable Druggable Genome-Wide*
496 *Mendelian Randomization Identifies Repurposing Opportunities for COVID-19*.
497 *Epidemiology*; 2020. doi:10.1101/2020.11.19.20234120
- 498 26. Nemoto M, Hattori H, Maeda N, et al. Compound heterozygous TYK2 mutations underlie
499 primary immunodeficiency with T-cell lymphopenia. *Sci Rep*. 2018;8(1):6956.
500 doi:10.1038/s41598-018-25260-8
- 501 27. Hellquist A, Järvinen TM, Koskenmies S, et al. Evidence for Genetic Association and
502 Interaction Between the *TYK2* and *IRF5* Genes in Systemic Lupus Erythematosus. *J*
503 *Rheumatol*. 2009;36(8):1631-1638. doi:10.3899/jrheum.081160
- 504 28. Sigurdsson S, Nordmark G, Göring HHH, et al. Polymorphisms in the Tyrosine Kinase 2
505 and Interferon Regulatory Factor 5 Genes Are Associated with Systemic Lupus
506 Erythematosus. *Am J Hum Genet*. 2005;76(3):528-537. doi:10.1086/428480
- 507 29. , The Wellcome Trust Case–Control Consortium (WTCCC) and Alastair Compston, Ban
508 M, Goris A, et al. Replication analysis identifies TYK2 as a multiple sclerosis susceptibility
509 factor. *Eur J Hum Genet*. 2009;17(10):1309-1313. doi:10.1038/ejhg.2009.41
- 510 30. Cunninghame Graham DS, Morris DL, Bhangale TR, et al. Association of NCF2, IKZF1,
511 IRF8, IFIH1, and TYK2 with Systemic Lupus Erythematosus. McCarthy MI, ed. *PLoS*
512 *Genet*. 2011;7(10):e1002341. doi:10.1371/journal.pgen.1002341
- 513 31. Watford WT, O’Shea JJ. Human Tyk2 Kinase Deficiency: Another Primary
514 Immunodeficiency Syndrome. *Immunity*. 2006;25(5):695-697.
515 doi:10.1016/j.immuni.2006.10.007
- 516 32. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with
517 Covid-19. *N Engl J Med*. 2021;384(8):693-704. doi:10.1056/NEJMoa2021436
- 518 33. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of Tocilizumab in Patients
519 Hospitalized with Covid-19. *N Engl J Med*. 2020;383(24):2333-2344.
520 doi:10.1056/NEJMoa2028836
- 521 34. Salama C, Han J, Yau L, et al. Tocilizumab in Patients Hospitalized with Covid-19
522 Pneumonia. *N Engl J Med*. 2021;384(1):20-30. doi:10.1056/NEJMoa2030340

523

524

525 **Tables and Figures**

526 **Table 1.** Patient characteristics of Million Veteran Program participants

Characteristics	Million Veteran Program	
	Number (%)	
Total Patients	455,683	
Male	403,923 (89)	
Genetic Ancestry		
European	312,282 (68)	
African	84,523 (18.5)	
Hispanic	33,348 (7.3)	
Asian	4,692 (1.02)	
Other	20,568 (4.5)	
Risk Factors		
Obesity (phecode = 278)	195,989 (43)	
Hypertension (phecode = 401.1)	318,131 (69.8)	
Type 2 Diabetes (phecode = 250.2)	161,544 (35.4)	
Coronary Artery Disease (phecode = 411.4)	110,564 (24.2)	
Chronic Kidney Disease (phecode = 585.2)	64,002 (14.04)	

527
528
529

530
531
532
533

Table 2. Phenotypes sharing association with variants also associated with severe COVID-19 infection, with reduced odds of disease listed in order of p-value*.

Phenotype	OR (95% CI)	p-value	Gene (SNP)	SNP (MAF)	COVID-severity
Psoriasis	0.72 [0.67 - 0.77]	1.5×10^{-22}	<i>RAVER1</i>	rs74956615-A (0.02)	Both
	0.88 [0.86 - 0.91]	1.35×10^{-17}	<i>TYK2</i>	rs11085727-T (0.3)	Critical
Rosacea	0.84 [0.81 - 0.89]	2.5×10^{-12}	<i>HLA-DPBI</i>	rs9501257-G (0.2)	Critical
Seborrheic dermatitis	0.86 [0.83 - 0.9]	1.8×10^{-10}	<i>RAVER1</i>	rs74956615-A (0.02)	Hospitalized
Psoriatic arthropathy	0.81 [0.76 - 0.87]	3.5×10^{-9}	<i>TYK2</i>	rs11085727-T (0.3)	Critical
	0.60 [0.51 - 0.71]	9.5×10^{-10}	<i>RAVER1</i>	rs74956615-A (0.02)	Hospitalized
Rheumatoid arthritis	0.79 [0.73 - 0.85]	1.0×10^{-9}	<i>RAVER1</i>	rs74956615-A (0.02)	Hospitalized
Vitiligo	0.69 [0.6 - 0.81]	2.4×10^{-6}	<i>CCHCR1</i>	rs143334143-A (0.09)	Critical
Sarcoidosis	0.73 [0.64 - 0.83]	4.3×10^{-6}	<i>CCHCR1</i>	rs143334143-A (0.09)	Hospitalized
	0.63 [0.51 - 0.78]	3.1×10^{-5}	<i>RAVER1</i>	rs74956615-A (0.02)	Hospitalized
Other disorders of liver	0.64 [0.53 - 0.78]	8.2×10^{-6}	<i>AC113414.1</i>	rs79833209-T (0.01)	Hospitalized
Hemorrhage from GI ulcer	0.85 [0.79 - 0.92]	4.0×10^{-5}	<i>ABO</i>	rs550057-T (0.2)	Critical
Other specified disorders of plasma protein metabolism	0.80 [0.72 - 0.89]	5.61×10^{-5}	<i>PTCHD4</i>	rs4715051-G (0.5)	Critical
Specific nonpsychotic mental disorders attributable to brain damage	0.82 [0.75 - 0.9]	6.0×10^{-5}	<i>PDE8A</i>	rs200678047-A (0.1)	Critical

534 *OR<0.9 and P<10⁻⁵ shown in table, full results in supplementary; if multiple related conditions, e.g. psoriasis,
535 psoriasis vulgaris, psoriasis and related disorders, description with lowest p-value selected shown in table.
536

537 **Fig 1.** Overview of variant selection and PheWAS analysis design.

538 **Fig 2.** PheWAS results of candidate SNPs from GWAS of critically ill and hospitalized COVID-
539 19. Significant associations between 48 SNPs from critical ill COVID GWAS (A) and 39 SNPs
540 from hospitalized COVID (C) and EHR derived phenotypes in the Million Veteran Program. The
541 phenotypes are represented on the x-axis and ordered by broader disease categories. The red line

542 denotes the significance threshold using false discovery rate of 10% using the Benjamini-
543 Hochberg procedure. The description of phenotypes is highlighted for the associations with FDR
544 < 0.1 and odds ratio < 0.90 or odds ratio > 1.10 . B) and D) A heatmap plot of SNPs with at least
545 one significant association (FDR < 0.1). The direction of effect disease risk is represented by
546 odds ratio. A red color indicates increased risk and blue color indicated reduced risk. The results
547 with odds ratio < 0.90 or odds ratio > 1.10 are shown.

548 **Fig 3.** Conceptual model of the relationship between *TYK2* (rs34536133) with reduced risk for
549 psoriasis, psoriatic arthritis, rheumatoid arthritis, and simultaneous increased risk of COVID-19
550 severity.

551 **Supplementary Figures and Tables**

552 **S1 Fig.** LDproxy plot showing *RAVER1* SNP rs74956615 has highest LD with missense variant
553 rs34536443 (*TYK2*).

554 **S2 Fig.** The PheWAS results of rs34536133 in MVP.

555 **S3 Fig.** The PheWAS results of 48 SNPs from critical ill COVID GWAS by each ancestry a)
556 European ancestry, b) African ancestry, c) Hispanic ancestry, and d) Asian ancestry.

557 **S4 Fig.** The PheWAS results of 39 SNPs from hospitalized COVID GWAS by each ancestry a)
558 European ancestry, b) African ancestry, c) Hispanic ancestry, and d) Asian ancestry.

559

560 **S1 Table.** List of lead variants from critical ill and hospitalized COVID GWAS included in the
561 study.

562 **S2 Table.** PheWAS results summary statistics by each ancestry and meta-analysis across four
563 ancestry for 48 lead SNPs identified from critical ill COVID GWAS.

564 **S3 Table.** PheWAS results summary statistics by each ancestry and meta-analysis across four
565 ancestry for 39 lead SNPs identified from hospitalized COVID GWAS.

566


567

COVID-19 GWAS Summary Statistics	Select COVID-19 Lead Variants	MVP Dataset	PheWAS
<ul style="list-style-type: none"> ❖ Critically ill vs Population (A1*) ❖ Hospitalized vs Population (B2*) 	<ul style="list-style-type: none"> ❖ SNPs clumped and pruned using 1000G reference panel ❖ FDR = 0.1 ❖ $R^2 < 0.1$ ❖ Distance threshold = 250kb 	<p>GENOTYPE DATA</p> <ul style="list-style-type: none"> ❖ 1000G imputed data ❖ Ancestry defined by HARE algorithm ❖ n=455,683 	<ul style="list-style-type: none"> ❖ PheWAS by ancestry ❖ Logistic or firth regression for association between SNPs with phecodes <ul style="list-style-type: none"> ❖ Covariates: 1st 20 PCs, age, age², sex
	<p>LEAD LOCI</p> <ul style="list-style-type: none"> ❖ n=48 from Critically ill vs Population GWAS (A1) ❖ n=39 from Hospitalized vs Population GWAS (B2) 	<p>PHENOTYPE DATA</p> <ul style="list-style-type: none"> ❖ ICD9/10 codes mapped to phecodes ❖ Case-control definition <ul style="list-style-type: none"> ❖ Case: ≥ 2 phecodes ❖ Control: 0 phecodes ❖ n<200 phecodes excluded by ancestry ❖ Total phecodes[#], n=1520 (EUR), 1206 (AFR), 858 (HIS), 176 (ASN) 	<ul style="list-style-type: none"> ❖ Transethnic meta-analysis ❖ Replication in UK Biobank


* From Host Genetics Initiative;

EUR = European Ancestry, AFR = African Ancestry, HIS= Hispanic Ancestry, ASN = Asian Ancestry


A.




B.




C.




D.



Direction of effect ▲ Risk ▼ Protective





Partial LoF of signal transduction for IL-12, IL-23 and Type I Interferons



Reduced risk of psoriasis, psoriatic arthritis,
and rheumatoid arthritis



Increased risk of viral infection
and
COVID-19 severity